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Background:  There is limited published data regarding the initiation of intravenous prostacyclins in children with pulmonary hypertension 
(PH). Knowledge of the relative frequency of prostacyclin drugs being utilized for initiation, length of stay, and inpatient costs may inform 
clinical practice.
methods:  All patients 2 to 21 years of age admitted to a Pediatric Health Information System member hospital with a diagnosis of primary 
pulmonary hypertension (ICD9 416.0) from 2005 to 2014 were identified. For each patient, we considered the first admission during 
which there was an IV prostacyclin drug charge as the initiation admission. Demographics, length of stay (LOS), prostacyclin initiated (i.e. 
epoprostenol or treprostinil), and other procedures during the initiation admission were assessed. Costs were calculated using hospital-
reported cost to charge ratios and expressed in 2014 US Dollars.
results:  Among 1,457 children admitted with primary PH, 280 (19%) were initiated on IV prostacyclin (epoprostenol n=195 and treprostinil 
n=85). The median proportion of PH patients initiated per hospital was 16% (range 0-53%). Mean age at initiation was 10.1 ± 5.6 years, 
57% were female, and 52% had at least 1 comorbidity. Epoprostenol predominated early, accounting for 97% of total initiations in 2005; 
however since 2011, treprostinil initiation has been predominant (52-67% of initiations/year). Children initiated on treprostinil had shorter 
total (4 [2-9] vs. 8 [4-18] d) and ICU LOS (1 [0-4] vs. 4 [0-10] d) and lower in-hospital mortality (1.2 vs. 11.8%; p<0.01 for each). Inpatient 
costs were also lower for treprostinil initiation ($23,785 [11,782 - 40,655] vs. $32,976 [11,904 - 94,553], p=0.03).
conclusion:  Intravenous prostacyclin initiation is common in children with primary PH, with marked increase in treprostinil initiation over 
the last decade. Though treprostinil initiation is associated with shorter LOS and lower hospital costs, post-discharge outcomes data are 
needed to fully inform decision making about the relative benefits of drug choice.
